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Summary
Stroke is a major health problem despite the great efforts made worldwide to fight 
against it. Despite therapeutic achievements to treat ischemic stroke patients in stroke units 
with tissue plasminogen activator (tPA), prevention remains the most powerful strategy to 
cure this complex disease. Stroke is a heterogeneous and multi-factorial disease caused by 
the combination of vascular risk factors, environment, and genetic factors. These risk factors 
can be modifiable or non-modifiable. 
Recently, a great emphasis has been given to the investigations of genetic factors and 
stroke risk, which may lead to the discovery of new biomarkers for prevention, diagnosis and 
to the alternative strategies for stroke treatment.  Ischemic stroke must be treated as an emer-
gency. Immediate transportation to a nearest hospital, preferably a stroke unit, cautious low-
ering of excessive blood pressures (>220/120mmHg) and ab stention from heparin and aspi-
rin are the most important measures in the pre-hospital care for a stroke patient. Intravenous 
thrombolysis in a 3-hour window is the only approved treatment, but it is time-dependent. 
In severe strokes with occlusion of large intracranial arteries, mechanical recanalization is 
increasingly used.  In order to improve stroke care in rural and urban areas where there is no 
organized stroke unit, it is useful to establish a stroke network, which functions according to 
telemedicine and teleneurology rules.  
Keywords: cerebrovascular disease; ischemic stroke; stroke prevention; risk factors; 
stroke management; thrombolysis; telemedicine; teleneurology.
INTRODUCTION
The devastating stroke consequences have enormous personal, social and eco-
nomic impact on oneself and the society. Stroke is the second leading cause of death 
worldwide. Its burden increases as the population ages and the incidence of the 
factors such as hypertension and diabetes increase across the globe [1]. Therapeutic 
strategies such as stroke unit care and treatments including tissue plasminogen ac-
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tivator (tPA) have been developed to treat acute stroke more effectively and lessen 
the amount of disability that the disease carries [2]. However, these modalities are 
not available universally in developed countries and scarcely at all in developing 
ones, with t-PA utilization of less than 1 in 10 patients where it is even available 
[3]. More than 75% of strokes each year are first-ever strokes, making the primary 
prevention of utmost importance. Although stroke is a clinical diagnosis with many 
sub-classifications and distinct yet sometime overlapping entities, the identity of 
the risk factors is well known with many treatments readily available. The disease 
can be controlled, and perhaps largely prevented, thus achieving a sizeable public 
health benefit. 
The stroke risk factors can be subdivided into non-modifiable (age, sex, race-eth-
nicity, genetic variations and predispositions) and modifiable (hypertension, dia-
betes, dyslipidemia, atrial fibrillation, carotid artery stenosis, smoking, poor diet, 
physical inactivity and obesity).  An individual risk factor may contribute to each 
subclassification of stroke differently, and there is a large overlap or risk factors with 
cardiovascular and peripheral vascular disease. In this paper we will discuss the 
management of traditional and novel risk factors in stroke prevention, as well as 
management of stroke itself.  
STROKE PREVENTION AND MANAGEMENT   
Hypertension is the most important modifiable risk factor for stroke. Several 
studies have concluded that it accounts for more than the third of the stroke burden 
and maybe as much as half of all strokes [4]. The control of high blood pressure 
(BP) contributes to prevention of first strokes but also of renal and heart failure 
and possibly cognitive decline and frank dementia [5]. It has been shown that for 
every 20-mmHg increase in systolic and 10-mmHg increase in diastolic BP greater 
than 115/75 mmHg, there is a 2-fold increase in mortality associated with stroke 
and coronary disease [6]. Conversely, a 10 mmHg reduction in systolic BP has been 
shown to lower the stroke risk by about a third in primary and secondary stroke 
prevention [7,8].  These benefits also extend to the elderly, where in one study, a 36% 
reduction was found in the incidence of stroke for patients over the age of 60 who 
were treated with a thiazide diuretic with or without a beta-blocker. A more recent 
study of patients over the age of 80 showed that lowering the mean systolic BP by 15 
mmHg and mean diastolic BP by 6.1 mmHg lowered the rate of fatal strokes by 39% 
after 2 years of treatment [9]. A meta-analysis of 31 trials, with 190606 participants, 
showed the benefits for educed BP in both younger (<65 years) and older (≥65 years), 
implying that the benefits from better pressure control can be reaped at any age [10]. 
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A more intensive regimen appears to be more beneficial: in the ACCORD, a 5,000 
patient study of those with diabetes, the patients who were in a more intense BP 
lowering group < 120, had a significantly lower risk of stroke after a follow-up of 4.7 
years compares to those with a BP lowering goal of <140 [11]. While the BP lowering 
has reduced the risk for all stroke subtypes, these findings are more pronounced for 
hemorrhagic strokes.
A comprehensive evidence-based approach to treatment of hypertension is 
provided by the Eighth Report of the Joint National Committee on Prevention, De-
tection, Evaluation, and Treatment of High Blood Pressure [12]. Several categories 
of antihypertensive medications such as thiazide diuretics, b-adrenergic receptor 
blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor 
blockers (ARBs), and calcium channel blockers (CCBs) have been shown to redu-
ce the risk of stroke in patients who are hypertensive [10,13]. Thiazide-type diure-
tics were originally recommended as the preferred initial drugs of treatment for 
most patients. [14] A more recent meta-analysis, however, has shown that with a 
few exceptions (beta-blockers after a recent myocardial infarction and additional 
benefits of CCBs) all the different classes of BP-lowering medications produced a 
similar reduction in the incidence of stroke and cardiovascular disease for a given 
reduction in BP [15].
BP control can be achieved in a vast majority of patients, with most requiring 
combination therapies and often more than 2 antihypertensive medications. Un-
fortunately, BP is controlled in less than a quarter of the hypertensive population 
worldwide. Given the importance of hypertension as a stroke risk factor, and the 
abundance of effective treatments available, providing effective population-wide 
but patient-specific interventions remains a major public health care challenge. 
Diabetes is an established risk factor for all vascular events in general and is-
chemic stroke in particular. Individuals with type 2 diabetes also have an increa-
sed vulnerability to atherosclerosis and an increased prevalence of hypertension, 
hyperlipidemia and obesity. Cardiovascular disease and ischemic stroke develops 
earlier in patients with diabetes, and strokes in patients with diabetes tend to have 
a heavier morbidity burden. American Diabetes Association recommends a mul-
ti-faceted approach to optimal health in diabetics; not only controlling the blood 
glucose, but also aggressive treatment of associated cardiovascular risk factors, 
with lower targets than for the general population. Surprisingly, recent studies have 
shown that aggressive treatment of blood glucose was very effective in preventing 
mircovascular complications of diabetes, but had no statistical effect on reduction 
of macrovascular events, including stroke [16,17]. However, the evidence that a mul-
tifactorial approach (reduced intake of dietary fat, light to moderate exercise, ce-
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ssation of smoking) reduces stroke and cardiovascular risk in type-2 diabetics is 
supported by subgroup analyses of diabetic patients in large clinical trials. In the 
UK prospective Diabetes Study Group, comparing a tight BP control group (mean 
BP 144/82 mmHg) vs less stringent control group (mean BP 154/87 mmHg) resulted 
in a reduction of 44% of fatal and non-fatal stroke between the two groups. Another 
study found that adding a statin to existing treatments in high risk patients resulted 
in a 24% reduction in strokes. The Collaborative Atorvastatin Diabetes Study evalu-
ated statin therapy in diabetic patients as a primary prevention of vascular events 
(18). A total of 2838 people with type 2 diabetes were enrolled, and the trial was sto-
pped early due to its efficacy points being met:  37% reduction the primary vascular 
events in general, and a 48% reduction of strokes in particular [18].
Good glycemic control involves appropriate insulin therapy and professional 
dietary and lifestyle therapy for type 1 diabetics and weight loss, increased physical 
activity and, if need be, oral and injectable hypoglycemic agents for type 2 diabetics. 
Treatment of adults with diabetes, especially those with additional risk factors, with 
a statin to lower the risk of a first stroke is recommended. Studies have shown that a 
multi-faceted approach to controlling diabetes and concomitant risk factors leads to 
significant reduction in cardiovascular events and stroke.
Many epidemiologic studies found no consistent relationship between choleste-
rol levels and overall stroke risks. However, there is evidence that there is a positive 
correlation between total and low density lipoprotein (LDL) cholesterol levels and 
the risk of stroke. Conversely, high density lipoprotein (HDL) cholesterol levels have 
been associated with reduced risk of ischemic stroke across many sub-populati-
ons. Moreover, in high risk patients, lowering cholesterol with statins (HMG-CoA 
reductase inhibitors) has been shown to significantly reduce the risk of transient 
ischemic attack or non-cardioembolic stroke [19]. Several meta-analyses have shown 
that lowering the LDL cholesterol by 1.0 mmol/L reduced the risk of ischemic stroke 
by about 20% [20]. The beneficial role of statins for primary and secondary stroke 
risk reduction for those with high risk for cerebrovascular disease risk has been 
documented [18]. It has estimated that statins prevent 9 strokes per 1000 high risk 
patients or in those with coronary heart disease treated over the period of 5 years. 
Earlier concerns of statins increasing the risk of hemorrhagic stroke have not been 
substantiated by a recent meta-analysis, although the topic is still under debate and 
caution should be exercised [21,22].
The benefit of rosuvastatin in cutting the risk of myocardial infarction in half 
in those patients who were apparently healthy but had elevated levels of C-reactive 
protein hints at the many pleotropic effects of statins [23]. Although this class of 
drugs is very well studied, the way it protects the brain and the heart is not entirely 
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clear. It may decrease platelet aggregation, stabilize plaques, lower BP and reduce 
inflammation. There has been further speculation that they may have neuropro-
tective properties, improve endothelium function, decrease smooth muscle proli-
feration and increase the number of circulating endothelial progenitor cells. Intri-
guing results have shown statins to increase nitric oxide production and P-selectin 
expression and up-regulate tissue-type plasminogen-activator. It is unclear if statins 
lower the risk of stroke by lowering the LDL, or by any of the above and maybe 
yet-unknown mechanisms. Other surrogate markers for artherosclerosis, such as 
carotid intima-media thickness (cIMT), may prove to be useful in monitoring the 
progression of and treatments against stroke and other vascular diseases [24].
Non-statin lipid-modifying therapies may also offer stroke protection, although 
the studies are less equivocal. Niacin treatment has been shown to increase HDL 
as part of a combination therapy. Evidence has been mixed on the exetimibe/statin 
combinations and if they are superior to mono-statin therapies. Fibrates have been 
shown to decrease the risk of coronary events and retinopathy, but not that of ische-
mic stroke [25]. Fibrates, Niacin, exetimibe and omega-3 fatty acids each regulate 
serum lipids by different mechanisms and a combination therapy may be the final 
answer in achieving desired lipid control. National Cholesterol Education Program 
III [26] guidelines for the management of patients who have not had a stroke and 
who have elevated total cholesterol or elevated non–HDL cholesterol in the presen-
ce of hypertriglyceridemia have been endorsed in the US [26]. The updated clinical 
guidelines for cholesterol testing and management (ATPIV) from the Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults were 
published at the end of 2012 [12].
Although the benefits of statin therapy outweigh the low risk of serious side 
effects, there are still some populations for which more data on the safety of li-
pid-lowering therapies are needed to clarify the risk associated with the effect of 
treatment, especially for older persons (>70 years of age) and women. More clinical 
trials and further research for optimal lipid-lowering strategies are needed as the 
complex relationship between dyslipidemia, atherosclerosis, stroke and cerebrovas-
cular disease exists and has not been entirely elucidated.
Metabolic syndrome is defined by a cluster of interconnected factors that in-
crease the risk of atherosclerosis, cerebrovascular disease, stroke, and diabetes 
mellitus type 2. Its components are dyslipidemia (elevated triglycerides and apoli-
poprotein B (apoB)-containing lipoproteins, and HDL), elevation of arterial BP and 
impaired glucose homeostasis, with abdominal obesity and/or insulin resistance 
[12,26,27]. More recently, other factors such as proinflammatory state, oxidative 
stress, and non-alcoholic fatty liver disease have been suggested to play an impor-
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tant role in metabolic syndrome, making its definition even more complex. To date 
the most used definition for metabolic syndrome is the NCEP ATP III definition 
(26). All the components of metabolic syndrome are involved in conferring risk of 
stroke and cardiovascular disease. The adjusted hazard ratio (HR) for incident isch-
emic stroke associated with metabolic syndrome ranges between 2.1 and 2.5 in pro-
spective studies, and a HR as high as 5.2 has been reported [28,29]. In a cohort of 
14,284 patients, patients with metabolic syndrome but without diabetes exhibited 
a 1.49-fold increased risk of ischemic stroke or transitory ischemic attack, whereas 
those with frank diabetes had a 2.29-fold increased risk [29]. The relative odds for 
ischemic stroke or transitory ischemic attack, associated with presence of metabolic 
syndrome, were 1.39 in men and 2.10 in women. In NOMAS, a significant associa-
tion between the metabolic syndrome and ischemic stroke risk was reported to be 
independent of other confounding factors including age, education, physical activ-
ity, alcohol use, and current smoking [30]. The prevalence of metabolic syndrome 
in NOMAS was 49%, and differed by sex (39% in men, 55% in women, p<0.0001) as 
well as race-ethnicity (56% in Hispanics, 41% in blacks, and 39% in whites, p<0.0001). 
Interesting, the effect of the metabolic syndrome on stroke risk was greater among 
women (HR=2.0; 95% CI, 1.3 to 3.1) than men (HR=1.1; 95% CI, 0.6 to 1.9) and among 
Hispanics (HR=2.0; 95% CI, 1.2 to 3.4) compared to blacks and whites. 
Metabolic syndrome is also associated with subclinical atherosclerosis. In NO-
MAS, we have shown an independent association between metabolic syndrome and 
ultrasonographic subclinical measures of atherosclerosis including carotid plaque 
and carotid stiffness [31]. Therefore, an early identification of people at high risk for 
vascular accidents by evaluating subclinical markers of atherosclerosis is prudent in 
order to initiate preventive treatments.
Although the existence of metabolic syndrome as a separate entity has been re-
cently questioned, individuals with a cluster of the risk factors that comprise meta-
bolic syndrome should be aggressively treated for hypertension, dyslipidemia and 
diabetes.  Patients with metabolic syndrome have a greater risk of stroke and other 
vascular diseases and therefore “a major breakthrough related to the concept of the meta-
bolic syndrome is the recognition of the high cardiovascular risk in subjects with a cluster of 
mild abnormalities or with a cluster of abnormalities that are not regarded as driving forces 
in cerebrovascular disease” [32]. 
Atrial fibrillation is a common cardiac arrhythmia and a frequent cause of car-
dioembolic strokes. It account for up to 20% of all ischemic stroke, and the presence 
of atrial fibrillation independently increases the risk of these events by up to 5-fold 
[33]. The incidence of atrial fibrillation increases with age, with as many as 10% of 
the population experiencing atrial fibrillation in their 80s [34] and the number of 
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affected patients may reach 12 million just in the U.S. by 2050. Despite its increasing 
burden, atrial fibrillation is also arguably one of the best-studied causes of stroke 
with dozens of randomized trials and well-established evidence-based recommen-
dations regarding effective medical treatments.  
Stroke risk stratification models have been developed and validated. CHADS2 
(Congestive heart failure, Hypertension, Age, Diabetes, Stroke/TIA) is the most well-
known stratification system [35]. It subdivides patients based on the independent 
predictors of stroke in those with atrial fibrillation and offers validated recommen-
dations of anticoagulation vs antithrombotics therapy based on the scale scores. 
Several other models for predicting stroke risk, (such as the National Institute for 
Health and Clinical Excellence (NICE) guidelines and CHADS2-VASc and bleeding 
risk (HAS-BLED) have since been developed [36].
Anticoagulation and antithrombotic therapies remain the main agents for stro-
ke preventions for those with atrial fibrillation. Warfarin is the most commonly 
used anticoagulant that is cheap and exceedingly effective in preventing ischemic 
stroke: a recent meta-analysis showed a reduced risk of cardioembolic stroke of 64% 
for those on warfarin vs only 22% for those on aspirin. Warfarin also provides an 
almost 40% relative risk reduction compared to anti-platelet therapies [37]. Despite 
its effectiveness, this anticoagulant has several limitations (narrow therapeutic win-
dow, many drug and diet interactions, frequent and inconvenient monitoring) and 
has been under-utilized [38]. It is difficult to keep in range with only two-thirds of 
patients in clinical trials and little more than half in the community setting being in 
the therapeutic range. 
Given the utilization gap for warfarin, several novel oral anticoagulants that are 
just as effective, have a better side effect profile and require less monitoring have 
been developed, tested and approved. The three novel oral anticoagulants that have 
shown the most promising effectiveness and safety data are Dabigatran [39], Riva-
roxaban [40], and Apixaban [41]. They all exhibit a stable pharmacological profile, 
very few drug-drug interactions and are almost unaffected by the patients’ diet. 
Very few patients (renal impairment or body weight extremes) require regular mo-
nitoring. They appear to be as effective, and in some cases superior to warfarin, with 
a much improved side effect profile. Less intracranial bleeding, arguable the most 
feared complication of coumadin, has been observed. These new agents will likely 
completely change how we treat patients with atrial fibrillation and lead to a greater 
reduction of cardioembolic strokes in the future [42].
Other times of cardiac disease that contribute to the risk of ischemic stroke 
include congestive heart failure, myocardial infarction, dialted cardiomyopathy, 
valvular heart disease (eg. mechanical valves, mitral valve prolapse, etc) and con-
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genital defects [eg. patent foramen ovale, atrial septal defect and aneurysm]. All 
patients with prosthetic valves should be anti-coagulated. The rate of thrombo-
embolism is reduced by half with antiplatelet therapy and by more than 75% with 
anticoagulation. Patients with congestive heart failure have a higher risk of stroke 
(2-3 fold) and are more likely to incur more significant stroke-related morbidity and 
mortality compared to those without heart failure [43]. Low ejection fraction (espe-
cially below <30%) has been identified as a risk factor for stroke, however, studies on 
the best treatments for this condition remain inconclusive. Presence of aortic arch 
atheroma is associated with increased risk of ischemic stroke. Congenital defects, 
while relatively common, contribute to the burden of stroke only in relatively spe-
cific circumstances. Most of these cardiac abnormalities and the potential thrombi 
that they produce require all and careful cardiac workup for detection, including a 
transthoracic and transesophageal echocardiography, and extensive cardiac moni-
toring with telemetry and often a more protracted outpatient cardiac event recorder.
Carotid stenosis of 50% or greater can be found in about 5-10% of people who 
are older than 65, and the prevalence of a severe asymptomatic carotid stenosis has 
been found in 3.1% of the population [44]. Data from observational studies and clini-
cal trials indicate an annual risk of stroke attributable to extracranial carotid to have 
increased with the degree of stenosis (from less than 1% a year for a <80% stenosis to 
4.8% per year for a >90% occlusive lesion). In Asymptomatic Carotid Atherosclero-
sis Study (ACAS), patients with asymptomatic carotid artery stenosis of ≥60% were 
randomized to carotid endarterectomy (CEA) or best medical management, with 
the results showing the primary outcome of ispilateral stroke, death or any peri-
operative stroke to be 5.1% for surgical candidate and 11% for patients treated medi-
cally over 5 years, with an absolute risk reduction of 1% a year [45]. Asymptomatic 
Carotid Surgery Trial (ACST) randomized asymptomatic patients with significant 
carotid stenosis (>60%) for immediate surgery vs. medical management and were 
followed for a mean of 3.4 years. The study found the overall 5-year risk of stroke 
or perioperative death to be 11.8% with deferred surgery and 6.4% with immediate 
endarterectomy. In the subgroup analysis, CEA appeared to be more beneficial for 
men than women, and in younger patients, more than older individuals. A more 
recent study, Asymptomatic Carotid Embolic Study (ACES), of patients who were 
followed for 2 years and had a asymptomatic carotid stenosis of at least 70% and 
were noted to have embolic signals found to have a significantly higher risk of ip-
silateral stroke compared to those without any emboli, suggesting the detection of 
embolization on transcranial Doppler may be used for additional risk stratification 
[46]. The benefit of endarterectomy in asymptomatic stenosis is dependent on the 
surgical risk. Trials of carotid surgery for asymptomatic carotid disease reduced the 
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risk of stroke by about 1% per annum, while the perioperative stroke rate is 3%.  Me-
dical management should be offered to most patients and only high-volume centers 
with complication rate of ≤3% should contemplate the surgical procedure. It appears 
that men and those with life expectancy of more than 5 years will derive the most 
benefit in appropriate centers [47,46].  Most physicians, however, are not aware of 
CEA complication rates at their institutions. The best medical management has been 
evolving with wider use of antiplatelet agents, blood pressure and lipid lowering 
drugs, reducing the risk of stroke to 1% [48] and therefore the above relative benefit 
of CEA may need to be recalibrated.
Carotid angioplasty and stenting (CAS) was developed as a less invasive proce-
dure compared to carotid endarterectomy.  It has emerged as an alternative for pati-
ents who are high surgical risks, have many medical comorbidities, previous neck ra-
diation, contralateral laryngeal nerve palsy or surgically-suboptimal anatomy. Since 
its invention over 20 years ago, the technique has evolved to more sophisticated and 
intricate stents, embolic protection devices and increasing operator experience. The 
Stenting and Angioplasty with Protection in Patient at High Risk of Endarterectomy 
(SAPPHIRE) Trial shows that stenting was non-inferior to CEA among high-risk 
surgical patients. The comparison of CEA and CAS has been extensively studied, 
often producing contradictory and confusing results. On one hand, multiple studies 
have shown that CAS is not as safe as CEA, especially in symptomatic patients, with 
the International Carotid Stenting Study (ICSS) being the latest addition to the mix. 
[49] On the other hand, Carotid Revascularization Endarterectomy versus Stenting 
Trial (CREST) found equal risk of composite primary outcome of stroke, MI or death 
in patients undergoing CAS or CEA [50]. The challenge of comparing three different 
modalities lie in the practice of modern medicine itself: the rapid evolution of me-
dical management, CEA and CAS know how always slanting the risk-benefit ratio 
in a different direction. Overall, we have rapidly improving techniques for effective 
prevention of stroke from asymptomatic carotid stenosis.
Elevated plasma levels of homocysteine as a risk factor for stroke has been tra-
ditionally well recognized in atherothrombotic vascular diseases including stroke. 
It is believed that homocysteine induces endothelial platelet dysfunction, by redu-
cing molecular nitric oxide. Folic acid and cobalamin have been shown to effectively 
reduce elevated homocysteine levels, however, clinical trials have failed to show 
that this translates into better cardiovascular or stroke outcomes [51,52]. Inflamma-
tion markers seem to be unaffected by lowering homocysteine in secondary stroke 
prevention, although it may have a role in patients with genetic predisposition to 
hyperhomocysteinemia or those who lack proper dietary folate intake.
18
Rad 517. Medical Sciences, 39 (2013) : 9-33
V. Demarin et al: Current trends in stroke management 
Cigarette smoking is a well-established and modifiable risk factor for both is-
chemic and hemorrhagic strokes. Several meta-analysis have established cigarette 
smoking to impart a 2-fold increase in the risk of ischemic stroke an 3-fold increase 
of subarachnoid hemorrhages [54]. The most effective preventive measure is to not 
smoke or be exposed to smoke. Although quitting smoking is difficult to achieve, 
it does carry significant benefits, with rapid reduction in the risk of stroke within 
several years of cessation. 
Alcohol consumption has been shown to have to have a J-shaped relation to risk 
of stroke, with light to moderate consumption (≤1 drink a day for women and ≤ 2 
drinks a day for man) decreasing the risk of stroke to 0.3 to 0.5, but the risk incre-
asing to 2 for heavier alcohol use (≥3 drinks) a day [54]. The relative risk is always 
increased for hemorrhagic strokes, regardless of the amount consumed. Alcohol in 
light to moderate quantities increases HDL cholesterol reduces platelet aggregation 
and lowers fibrinogen levels, while heavier use can lead to hypertension, hypercoa-
gulability and atrial fibrillation [55]. Alcohol consumption should not be advocated 
as a way to prevent stroke, however, as alcoholism is a major public health problem 
and the risks of excessive intake remain great. 
Abuse of illicit drugs such as cocaine in its various forms, heroin and ampheta-
mines are associated with increased risk of both ischemic and hemorrhagic strokes 
by elevating the blood pressure and platelet aggregation, and inducing vasospa-
sm and cardiac arrhythmias. Diet has been associated with the risk of stroke, with 
increased fruit and vegetable consumption having an inverse relationship to the 
risk of stroke in a dose-response manner;  for example, for each serving per day 
increase in fruit or vegetable intake, the risk of stroke was reduced by 6% in one 
study. Research has shown that reducing salt intake improves cardiovascular and 
cerebrovascular health, although a recent review found no relation to salt intake 
and chronic heart disease morbidity and mortality [56]. Adherence to Mediterrane-
an diet has also now proven to have a positive protective effect on cerebrovascular 
and cardiovascular disease [57].
Physical inactivity is another modifiable risk factor of stroke [58]. Physical acti-
vity has been shown to be beneficial in a dose-response pattern with more intensive 
physical activity providing greater benefits than light to moderate activity. The pro-
tective effects of physical activity are likely derived from lowering of body weight 
and BP and better glycemic control. 
Obesity and body mass index (BMI) are risk factors for stroke, with associations 
to hypertension, dyslipidemia and glucose intolerance [59]. An obesity epidemic has 
been sweeping developed countries as well as developing nations such as India and 
China. The prevalence of metabolic syndrome worldwide, an entity that encom-
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passes several stroke risk factors, was alarmingly high a decade ago (24-50%) and 
given the recent trends is likely to have increased since then [59]. Although no trials 
linking weight loss to the risk of stroke exist, evidence exists that losing weight re-
duces the presence of risk factors that cause stroke:  in one meta-analysis an average 
weight loss of 5.1 kg reduced the systolic BP by 3.6-4.4 mmHg.  Diet and exercise 
which are discussed above can be effective in controlling this modifiable risk factor. 
Sleep related breathing disorders are common in patients with established car-
diovascular disease. Habitual snoring and obstructive sleep apnea (OSA) have been 
shown to be independently associated with stroke and snoring has been strongly 
associated with vascular events during sleep. A recent-meta-analysis of 29 studies 
has shown that up to three-quarters of all patients have OSA, with the highest inci-
dence of stroke occurring in patients with cryptogenic stroke, possibly establishing 
OSA an under-recognized stroke risk factor [60]. Hypoxemia, nocturnal hyperten-
sion and sympathetic surges have been postulated as some of many contributors 
to stroke in OSA patients. Decreased cerebral blood flow and impaired vasomotor 
reactivity has been observed even when the patients with OSA are not sleeping. 
Treatments with continuous positive airway pressure (CPAP) are non-invasive, and 
effective in reducing the risk of cardiovascular events and BP [61]. Further studies 
of OSA and other sleep disorders are on-going and may yield novels strategies and 
approaches in stroke prevention.
Aspirin has been shown as a well-established medication for primary stroke 
prevention. A recent meta-analysis showed a 32 % reduction in myocardial infarc-
tion in men but not women and a 17% reduction of the risk of stroke in women, but 
not men [62]. It is not clear why the sex difference exists, as the platelets seem to be 
inhibited equally in either sex, and no gender disparity was identified in studies 
in secondary prevention. A trial among diabetics with a history of atherosclerotic 
disease found Aspirin had no statistically significant effect on the rate of cerebro-
vascular events. Current guidelines indicate low-dose aspirin for women for whom 
the benefits may outweigh the risks and for patients with high CHD risk factors, but 
not for those at low risk or diabetics [63].
Stroke is a complex and multi-factorial disease caused by the combination of vas-
cular risk factors, environment, and genetic factors. Recently, the scientific commu-
nity put a great effort in understanding the genetic impact to the risk of stroke. 
Several epidemiological studies in families and twins have revealed a genetic com-
ponent to stroke risk and experimental and clinical research using novel technologi-
es have identified several genes directly or indirectly implicated in the mechanisms 
leading to stroke. The genetic contribution seems to be stronger in stroke patients 
younger than 70 years than in those who are older [64]. The strongest associations 
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have been found between stroke and single nucleotide polymorphisms (SNPs) in 
genes involved in inflammation, renin-angiotensin system, atherosclerosis, lipid 
metabolism, and obesity. (Matarin et al., 2010) However, few of these associations 
have been consistently replicated [65]. The innovation of a Genome-wide association 
study (GWAS) has allowed for identification of novel genetic loci without a specific 
hypothesis implicating a particular molecular pathway. The first GWAS for ische-
mic stroke was conducted using more than 400,000 unique SNPs in a cohort of 249 
patients with IS and 268 neurologically normal controls [66]. However, these data 
did not reveal any single locus conferring a large effect on ischemic stroke risk. 
Other ischemic stroke GWASs have been conducted using a meta-analysis approach 
combining large populations such as CHARGE (Cohorts for Heart and Aging Rese-
arch in Genomic Epidemiology), [67]. which consists of 4 prospective epidemiologi-
cal cohorts of nearly 19,600 subjects with 1,544 incident strokes. In CHARGE, 2 SNPs 
were identified on chromosome (ch) 12, in the region of 12p13, and replication was 
obtained for one (rs12425791 SNP; the hazard ratio 1.3 for all stroke, and 1.0 for IS). 
A large International Stroke Genetic Consortium and the NINDS SiGN (Stroke Ge-
netic Network) is currently conducting a GWAS of over 15,000 IS patients and 10,000 
controls and expected to have the results available within a year.
Since stroke is a complex disease probably related to multiple genetic loci and 
the interaction of environment and heredity, the study of the precursors of this com-
plex phenotype may be more rewarding. For example, the intermediate phenotypes 
as markers of subclinical disease such as cIMT, carotid plaque, arterial stiffness, 
and left ventricular mass; may be more helpful in identifying genes related to athe-
rosclerosis and stroke [64]. The genetic research of stroke may greatly enhance our 
knowledge of this complex diseases. It may contribute to the discovery of new stro-
ke biomarkers, which ultimately may be included in the stroke prevention, diagno-
sis, and treatment decisions. 
When ischemic stroke does occur, the earlier stroke treatment starts the better 
the out come. It is essential to minimalize the delay from symptom on set to the-
rapy. Intravenous thrombolysis with alteplase wi thin 3 hours is the only approved 
specific treatment of acute ischemic stroke. The benefit of thrombolytic therapy is 
time dependent [68,69]. For every 10 minutes of treatment delay, within 1-3 hours 
after stroke onset, 1 fewer patient out of 100 has a favourable outcome after systemic 
throm bolysis [69].
The majority of ischemic stroke patients unfortunately do not reach the hospital 
early enough to receive thrombolysis. For those patients, general acute stroke treat-
ment is of utmost importance [70].
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Prehospital stroke management starts with knowlede of stroke symptoms in 
general population, this being the cause of biggest delay in stroke treatment. Fol-
lowing the imporance of recognizing stroke, emergency department is crucial for 
successful stroke treatment [71]. It is usually the family members rather than the 
patients themselves contact emergency department. Informational campaigns dis-
tributed by mass media including TV’ internet, social networks, and newspapers, 
provide education and encouragment to make an emergency call immediately after 
suspecting stroke occurence. 
Apart from general public, emergency personnel and paramedics should also be 
continuously trained to improve preclinical stroke manage ment [72]. Patients with 
facial droop, prior stroke or TIA and severe clinical deficit are most probable to 
receive a correct preclinical diagnosis of stro ke, indicating that more subtle stro-
ke symptoms may sometimes be misinterpreted or overseen [73]. The Face-Arm-
Speech Test (FAST) is a simple acronim which can help identify stroke or TIA [74]. 
General practitioners should also be involved in preclini cal stroke management, 
and participate in continuous training to be able to urgently evaluate every suspec-
ted stroke and channel the patient accordingly. Emergency department transporta-
tion ensures faster hospital admission due to quicker arrival, compared to private 
transport [75]. Whenever possible, transportation should be to the nearest hospital 
with a stroke unit. Prenotification to the emergency department and stroke unit 
physicians during transport ensures quicker in-hospital management and better 
chances to receiving thrombolysis. 
During transport to the nearest hospital, patients should receive 0.9% saline in-
travenously. Heparin or aspi rin should not be given before exclusion of intracranial 
hemorrhage by a CT scan. Hypertension can be tolerated up to 220/120 mmHg wit-
hout lowering the BP. Oxygen should be supplied if saturation falls below 95% [76]. 
Upon arrival to the hospital the emergency department personnel should present 
the patient [73,75].
Immediate triage, neurological evaluation ircluding NIHSS, general physical 
examination, laboratory tests, and a native CT scan are needed [73]. Stroke or TIA 
mimics must be ruled out (including epileptic syncopes, sepsis [74], migraine with 
aura [77], or hypoglycemia). It is useful to implement in-hospital algorythms to 
speed up the evaluation and decision making.  
Irrespective of age, gender, stroke subtype or stroke severity, admission to a 
stroke unit significantly reduces death, post-stroke dependancy, as well as need for 
institutional care after stroke. Stroke units are hospital wards with spacialized mul-
tidisciplinary staff trained for treating acute stroke and stroke related complications. 
Stroke teams consist of doctors, nurses, physiotherapists, occupational therapists, 
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speech and language therapists and social workers [78]. Technical equipment in a 
stroke unit allows assessment of neurological status, monitoring of vital parameters 
within 72 hours after severe stroke, ensure early mobilization and rehabilitation 
after stroke.
In most cases  stroke is not acutely life-treatening, but majority of patients need 
stabilization of vital functions during the first hours to days after stroke. Treatment 
strategies aim at normalizing respiratory and cardiac functions, glucose, blood pre-
ssure, fluid balance, and at preventing stroke-related complications [76].
Stroke patients are at increased risk of cardiac arrhythmias, especially atrial 
fibrillation, myocardial infarction, heart failure or sudden death. Troponin levels 
can be elevated slightly during acute stroke, even in the absence of acute coronary 
syndrome, and thought to be due to stroke-related sympathoadrenal activation [79], 
making it necessary for every patient to have an ECG on admission. Further cardiac 
monitoring serves to maintain normal heart rates and can reveal paroxysmal atrial 
fibrillation as a common cause of stroke [76]. 
Hyperglycemia occurs frequently (30-40%; up to 60% in non-diabetics) in acute 
stroke and is associated with poor outcome and death, especially in patients without 
known diabetes [80]. Hyperglycemia was shown to be associated with hemorrhagic 
transformation of stroke  and larger infarct volumes (81). However, it is uncertain if 
correction of elevated glucose levels im proves clinical outcomes. To date, correction 
of glucose levels above 10 mmol/L with insulin, and below 2.8mmol/L with 10-20% 
glucose or dextrose bolus is recommended [76].
Hypertension is also common in acute ischemic stroke, and associated with 
increased risk of poor outcome. Due to impaired cerebral autoregula tion during 
acute stroke, every change in systemic blood pressure directly affects cerebral blo-
od flow. Hypertension may result in hemorrhagic transformation of the infarcted 
area, whereas hypotension may cause further da mage to the penumbra. Despite 
such pathophysiological considerations, the optimal blood pressure management in 
acute ischemic stroke is not known. It is also unclear whether early discontinuation 
from preexisting antihy pertensive treatment (about 50% of patients) is necessary 
[82]. Beneficial effects of early hypertension control could not be reproduced [83]. In 
the absence of con clusive data, current guidelines recommend moderate lowering 
of raised blood pressure over 220/120 mmHg, and over 185 mmHg systolic in throm-
bolysed patients using intravenous labetolol or urapidil [76], approxi mately by 15—
25% during the first 24 hours atrial fibrillationter stroke [84]. Sublingual nifedipine 
has been described to cause abrupt decrease in blood pressure, and is therefore not 
a drug of first choice. In clinical practice, after per missive hypertension during the 
first 24 hours within the mentioned limits for nonthrombolysed and thrombo lysed 
patients, antihypertensive medication may be con tinued or started from day 2.
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Evidence how to handle hypotension is even more scarce. Low blood pressure at 
stroke onset is unusual and is recommended to be raised with saline 0.9% or volu-
me expanders when associated with neurological deterioration. Inotropic support is 
only needed in pa tients with hypotension due to low cardiac output [76].
Oxygen should be supplied (usually 2-4 L/min via nasal tube) if saturation is 
below 95%. Saline 0.9% is rec ommended for fluid replacement during the first 24 
hours after stroke. Fluid balance and electrolytes should be further monitored in 
dysphagic patients with severe deficit or impaired consciousness. Pyrexia (body 
temper ature >37.5°C) should be treated with paracetamol and prompt the search for 
infections [76].
Bacterial pneumonia due to aspiration is one of the most frequent complications 
of acute ischemic stroke and should be treated with antibiotics. Aspiration occurs in 
patients with dysphagia or impaired conscious ness and may be prevented by fee-
ding by nasogastric tube, pulmonary physical therapy, and early mobiliza tion [76]. 
Prophylactic antibiotic treatment, in contrast, may be harmful [85].
Urinary tract infections also commonly oc cur in hospitalized patients, mostly 
due to indwelling catheters. Almost half of stroke patients suffer in continence at 
stroke onset (86), making urinary ca theterization at least temporarily needed. Anti-
biotics should be used once urinary tract infection is diagnosed. Bladder catheters 
should be removed as soon as possible. However, 25% and 15% of patients will be 
incontinent at discharge and one year after stroke [86].
Immobilization due to paresis is a risk factor for deep venous thrombosis (DVT) 
and consecutive pulmonary embolism (PE). Early mobilization, rehydration and 
sub cutaneous low molecular weight heparin can reduce the risk of DVT and PE in 
stroke patients without increasing the risk of hemorrhage [76,87]. 
Many stroke symptoms - hemiparesis, ataxia, vertigo, visual field defect, lower 
limb hypaesthesia, cognitive im pairment, and depression - as well as polypharmacy 
lead to impaired gait balance and expose patients to increased risk of injury and 
falls. Hypovitaminosis D can be seen within one week after hemiplegic stroke. Falls 
occur in up to 25% of acute stroke patients, leading to serious injury, including hip 
fractures, in up to 5%. Physical exercise, mobilization, and supplementation of vita-
min D, calcium, and biphosphonates can reduce fracture rates among acute stroke 
patients and should be provided in the acute setting. Drugs leading to postural in-
stability, e.g. neuroleptics, should be avoided whenever possible [88-90]
Confusion, agitation and delirium are common prob lems in the acute phase of 
stroke. A search for underlying treatable causes often reveals dehydration, electro-
lyte dysbalance, fever, substance withdrawal, or nonconculsive epileptic seizures. 
When sedation or neuroleptics cannot be avoided, choice of drugs should take into 
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account po tential side effects. Sedation can lead to impaired con sciousness and thus 
increase the risk of aspiration and falls, so substances with short half-time periods, 
such as lorazepame, may be preferred. Antipsychotics, among them risperidone, 
have been associated with in creased risk of cerebrovascular accidents in the elderly, 
risk of myocardial infarction in demented patients on cholinesterase inhibitors, and 
death [91,92]. The risk of cerebrovascular accidents seems to be greatest within the 
first weeks of drug intake, making the use of typical and atypical antipsychotics in 
the acute stroke setting even more hazardous. General recommendations are lack-
ing, and prescription will be an individual deci sion based on comorbitidy and esti-
mated harm if psy chotic symptoms are left untreated. 
Systemic thrombolysis with rt-PA within 3 hours is the only approved evidence-
based therapy of acute isc hemic stroke. Beyond 3 to 4.5 hours, intravenous throm-
bolysis remains effective and safe [68], but is yet un approved by European medical 
authorities. Cerebral he morrhage has to be excluded by CT scan before throm bolysis 
is started. As an off-label procedure, intravenous thrombolysis in the extended time 
window is routinely performed in experienced stroke centers. Data from the multi-
centre SITS-ISTR stroke registry showed that in 2009 there was a substantial incre-
ase (from 7% to 22%) in thrombolysis within 3 to 4.5 hours compared to 2008 [93]. 
However, the benefit of thrombolysis remains time-dependent (NNT in terms of a 
favourable outcome = 7 within 3 hours, 14 by 3 to 4.5 hours), [68]. Overall, the risk of 
SICH and mortality are slightly higher in patients thrombolysed within the exten-
ded time window, but the proportion of patients with favourable clinical outcome 
after 90 days is similar [93].
About 30% of strokes occur in people >80 years of age. Whereas approval criteria 
restrict thrombolysis to younger patients, it is now clear that older age is not a rea-
son to preclude someone from treatment: risk and benefit must be weighted. Elderly 
stroke patients have higher bleeding rates. Mortality is also higher, but so is pre-
stroke comorbidity. However, functional outcome in terms of mRS is significantly 
better in patients > 80 years after thrombolysis vs. without, and similar to younger 
patients [94,95].
In recent years, an increasing number of mechanical recanalization devices have 
been used to treat severe strokes with intracranial large artery occlusion as shown 
by CT angiography. The rates of good outcome (mRS = 0—2) in creased to 45 % with 
the latest techniques, rather acceptable for patients having very severe strokes [96]. 
For selection of patients the mismatch of cerebral blood flow and cerebral blood vo-
lume on con trast enhanced CT is used more and more instead of the time window. 
Perfusion CT has the advantage of being fast, widely available and less affected 
by arte facts than diffusion weighted and perfusion weighted magnetic resonance 
imaging.
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Considering  mentioned  evidence that acute stroke patients benefit of speciali-
zed treatment in stroke units, but this specialized treatment is expensive and there-
fore not available everywhere. In most countries expertise in acute stroke treatment 
is mainly concentrated in academic hospitals, whereas a majority of stroke patients 
is treated in local general hospitals where the level of stroke care is partially sub-
optimal [97].
In order to improve stroke care in rural and urban areas it is useful to establish a 
stroke network.  In order to take part in this kind of sophisticated stroke care, partic-
ipating centers need to fulfill a number of require ments, such as: 24 hours availabil-
ity of CT- or MR-imaging, Doppler-sonography, emergency laboratory diagnostics; 
securing a stroke care ward, with beds where all acute stroke patients of the hospital 
are concentrated, where monitoring of neurological status and vital parame ters as 
well as early mobilization of the stroke patients is possible; continuous treatment 
by physiotherapists, occupational therapists and speech ther apists; presence of a 
neurologist during the week and on call for emergencies during the weekend; the 
medical staff of the hospitals should be equipped with nurses, speech therapist and 
physiotherapist, as well as well as an additional phy sician [98].
These stroke teams have to complete a specific training program including: The 
training program is based on Standardized Optimized Procedures for diagnosis 
and treatment of stroke syndromes; Video training and certification in NIH-SS eval-
uation; Courses in transcranial Doppler sonography; Courses in swallowing disor-
ders and dysphagia treatment.
A continuous stroke education program must include ward rounds in the local 
hospi tals with one of the stroke experts every 3-4 months, newsletters and work-
shops is run ning in order to achieve further improvement of stroke care in the par-
ticipating hospi tals.
Therapeutic intervention in acute stroke requires urgent patient evaluation by 
physicians experienced in acute stroke to provide the best available care within 
critical time windows. Each hospital within the network should be equipped with 
a high-speed video conferencing system. In the local hospitals a second camera in 
a different position can be used. The interface of the local CT-scanners and MRI-
scanners are connected to the workstation which is situated in a special room, close 
to the emergency facilities of the regional hospitals in order to facilitate rapid patient 
evaluation. 
The stroke centers provide a 24-hours service with full-time stroke experts for 
teleconsultations. Contact is made up via telephone, the video connection is then 
established within minutes. The stroke specialist can download and analyze the CT 
or MRI-data from the server in the local hospital. Once the patient is in the exami-
26
Rad 517. Medical Sciences, 39 (2013) : 9-33
V. Demarin et al: Current trends in stroke management 
nation room the physician at the stroke center can talk with him or with the local 
physician. The stroke specialist is visible on a screen in the examination room. The 
remote-controlled camera is operated by the stroke specialist in order to zoom and 
focus on the areas of interest. Mean duration of a video examination is between 15 
and 20 minutes. Each teleconsultation is accomplished with a written report via 
electronic transmission. Indi cations to contact the stroke centers are clear cut [99].
CONCLUSION
Stroke remains a devastating and prevalent world-wide disease. The past seve-
ral decades of research have also shown it to be a partially-preventable one, with 
many risk factors, strategies, and treatments identified, carefully evaluated and stu-
died. A healthy diet and active lifestyle, careful control of modifiable stroke risk fac-
tors and access to regular health care are the keys to a successful stroke prevention 
strategy on both an individual and a public health level. 
In stroke treatment evry minute counts. Raised stroke awareness within the 
popu lation, rapid diagnosis by paramedics and primary care doctors, transporta-
tion by emergency deparment, hospital pre-notification and well organized in-hos-
pital algorhytms con tribute to rapid application of stroke treatment. The extended 
time window for systemic thrombolysis and recent data supporting thrombolysis in 
elderly patients >80 years of age offer the possibility that more patients receive this 
specific therapy for acute ischemic stroke. Acute general stroke management is best 
done at a multiprofessional stroke unit for 48-72 hours and deals with stroke-related 
metabolic, cardiorespiratory, inflammatory, and neuro psychiatric problems.
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Sažetak
Sadašnje smjernice za zbrinjavanje bolesnika s moždanim udarom
Unatoč konstantnoj borbi protiv moždanog udara u svijetu, on i dalje ostaje bitan zdrav-
stveni problem. Iako je postignut velik napredak u liječenju moždanog udara primjenom ak-
tivatora tkivnog plazminogena (tPA) u jedinicama za liječenje moždanog udara, prevencija 
ostaje najsnažnija strategija u liječenju te kompleksne bolesti. Moždani je udar heterogena 
i multifaktorijalna bolest uzrokovana kombinacijom vaskularnih čimbenika rizika, okoline 
i genetskih čimbenika. Na neke čimbenike rizika možemo utjecati, dok drugi ne ovise o 
nama. 
Danas je naglasak stavljen na istraživanja genetskih čimbenika kao rizika za moždani 
udar. Ova istraživanja mogla bi dovesti do otkrića novih bioloških markera za prevenciju, di-
jagnostiku i alternativnu strategiju u zbrinjavanju bolesnika s moždanim udarom. Ishemijski 
moždani udar mora se zbrinjavati kao hitno stanje. Najvažnije mjere prehospitalnog zbrinja-
vanja bolesnika s moždanim udarom uključuju pravovremeni transport u najbližu bolnicu, 
ako je moguće u jedinicu za zbrinjavanje moždanog udara, pažljivo snižavanje izrazito 
povišenog krvnog tlaka (> 220/120 mmHg) te suzdržavanje od davanja heparina i aspirina. 
Intravenska tromboliza u trosatnom vremenskom prozoru jedino je odobreno liječenje, ali 
je vremenski ovisno. U slučaju teškog moždanog udara kod kojeg dolazi do okluzije velikih 
intrakranijalnih krvnih žila sve se češće izvodi zahvat mehaničke rekanalizacije. Kako bi se 
unaprijedila skrb za bolesnike s moždanim udarom u ruralnim i urbanim područjima gdje 
nema organiziranih jedinica za liječenje moždanog udara, korisno je uspostavljanje mreže 
za moždani udar koja funkcionira prema pravilima telemedicine i teleneurologije. 
Ključne riječi: ishemijski moždani udar; prevencija; čimbenici rizika; zbrinjavanje bo-
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